725 reports of this reaction
1.5% of all CANAGLIFLOZIN reports
#19 most reported adverse reaction
DEHYDRATION is the #19 most commonly reported adverse reaction for CANAGLIFLOZIN, manufactured by Janssen Pharmaceuticals, Inc.. There are 725 FDA adverse event reports linking CANAGLIFLOZIN to DEHYDRATION. This represents approximately 1.5% of all 49,711 adverse event reports for this drug.
Patients taking CANAGLIFLOZIN who experience dehydration should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DEHYDRATION is a less commonly reported adverse event for CANAGLIFLOZIN, but still significant enough to appear in the safety profile.
In addition to dehydration, the following adverse reactions have been reported for CANAGLIFLOZIN:
The following drugs have also been linked to dehydration in FDA adverse event reports:
DEHYDRATION has been reported as an adverse event in 725 FDA reports for CANAGLIFLOZIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
DEHYDRATION accounts for approximately 1.5% of all adverse event reports for CANAGLIFLOZIN, making it a notable side effect.
If you experience dehydration while taking CANAGLIFLOZIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.